drugset
drugset / Trial / NCT00641329

CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD

NCT00641329 ↗

Phase 3 Completed 198 enrolled Addrenex Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if CLONICEL (clonidine HCl sustained release) is a safe and effective add-on to psychostimulant therapy in children and adolescents with attention deficit hyperactivity disorder (ADHD).

Timeline

Start
2008-02
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject CLONICEL Unknown 0.1 mg —
Subject CLONICEL Unknown 0.4 mg —

Indications

attention deficit-hyperactivity disorder